RAAS is activated in obesity children.
肥胖组儿童存在RAAS的异常激活。
The increased activity of RAAS may be regarded as an early risk marker for EH.
RAAS的活性增高可作为易患高血压病的早期预警指标。
The development of the drugs targeting RAAS offers more choices for treatment of hypertension.
作用于RAAS药物的研发为治疗高血压提供了更多的选择。
The renin-angiotensin-aldosterone system (RAAS) is a feedback system activated with volume depletion.
肾素-血管紧张素-醛固酮系统（RAAS）是一种能被容量丢失激活的反馈控制系统。
Aliskiren represents a new principle of blocking the RAAS, inhibiting renin directly and acting at the rate-limiting step.
阿利吉仑代表一种阻滞RAAS的新原理，直接抑制肾素并作用于限速阶段。
Salt and water depletion due to inability to conserve sodium in the TALH or DCT leads to activation of the RAAS and high aldosterone levels.
由于TALH或DCT不能保钠，因而会出现盐和水的丢失，继而会激活RAAS，使醛固酮水平升高。
We also assessed the impact of the treatments on RAAS components and biomarkers of inflammation, endothelial dysfunction, and cardiovascular risk.
我们同时评估了治疗对RAAS组成部分和炎症生物标记物、内皮功能障碍和心血管风险的影响。
Improving diastole function may connected with restraining over-activation of RAAS, reducing blood density and improving micro-circulation and so on indirectly.
改善舒张功能可能与抑制肾素-血管紧张素-醛固酮系统(RAAS)过度激活、降低血液粘稠度及改善微循环等间接作用有关。
Conclusion Propofol could decrease blood pressure, which may be due to its effect on the ATP sensitive KATP channels which could inhibit plasma renin activity (PRA) and RAAS.
结论异丙酚降压作用与其作用于KATP通道、抑制肾素活性，进而抑制肾素血管紧张素醛固酮系统有关。
Aldosterone inhibitors and ACE inhibitors help block the RAAS and help prevent potassium loss in the distal tubules. The body conserves potassium, and less oral potassium supplementation is needed.
醛固酮抑制剂和血管紧张素转换酶抑制剂可辅助阻断RAAS，并有助于防止远端肾小管钾的损失。身体保钾，这样可减少口服补钾量。
Aldosterone inhibitors and ACE inhibitors help block the RAAS and help prevent potassium loss in the distal tubules. The body conserves potassium, and less oral potassium supplementation is needed.
醛固酮抑制剂和血管紧张素转换酶抑制剂可辅助阻断RAAS，并有助于防止远端肾小管钾的损失。身体保钾，这样可减少口服补钾量。
应用推荐